Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...
The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...
Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...
In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...
Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...
MERCK & Co licenced an experimental cancer antibody from a closely held Chinese company in a deal worth US$588 million ...
The company will still have some catching up to do, as LM-299 is early in clinical development, with a phase 1 trial ...
After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...
Immutep's American depositary receipts jumped after the company reported positive data from a trial evaluating its drug Efti in combination with Merck's therapy Keytruda for treating non-small cell ...
Investor's Business Daily on MSN4h
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit TherapeuticsMerck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.
Analysts say the drug could emerge as a potential competitor to Merck’s blockbuster immunotherapy Keytruda. Keytruda is ...
Summit Therapeutics and its Chinese partner Akeso have a few competitors now.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback